A Randomized Controlled Trial of Vitamin D₃ Supplementation in African American Women

John F. Aloia, MD; Sonia Arunabh Talwar, MD; Simcha Pollack, PhD; James Yeh, PhD

Background: We conducted a randomized, placebo-controlled, double-blind trial to test the hypothesis that vitamin D₃ supplementation would prevent bone loss in calcium-replete, African American postmenopausal women.

Methods: Two hundred eight healthy black postmenopausal women, 50 to 75 years of age, were assigned to receive either placebo or 20 µg/d (800 IU) of vitamin D₃. Calcium supplements were provided to ensure a total calcium intake of 1200 to 1500 mg/d. After 2 years, the vitamin D₃ dose was increased to 50 µg/d (2000 IU) in the active group, and the study continued for an additional year. Bone mineral density (BMD) was measured every 6 months. Markers of bone turnover, vitamin D metabolites, and parathyroid hormone (PTH) levels were measured in serum.

Results: There were no significant differences in BMD between the active and control groups throughout the study. There was also no relationship between serum 25-hydroxyvitamin D levels attained and rates of bone loss. There was an increase in BMD of the total body, hip, and radius at 1 year in both groups. Over the 3 years, BMD declined at these sites by 0.26% to 0.55% per year. The BMD of the lumbar spine increased slightly in the placebo and active groups. There were no persistent changes in serum PTH levels or the markers of bone turnover, although there was a transient decline in PTH in both groups at 3 months. No significant adverse events were attributed to vitamin D supplementation.

Conclusions: There was no observed effect of vitamin D₃ supplementation on bone loss or bone turnover markers in calcium-replete, postmenopausal African American women. Further studies are needed to determine if these findings are applicable to women of other ethnic groups.

Arch Intern Med. 2005;165:1618-1623

There is consensus on the optimal calcium intake that should be recommended for reducing postmenopausal bone loss. Although it is recognized that vitamin D is important in calcium economy, optimal vitamin D intake is controversial. Serum 25-hydroxyvitamin D (25-OHD) is the best indicator of vitamin D status. Serum levels lower than 10 ng/mL (25 nmol/L) lead to rickets and osteomalacia, and levels lower than 20 ng/mL (50 nmol/L) may lead to secondary hyperparathyroidism and bone loss. Recent studies of the relationship of serum concentrations of 25-OHD to parathyroid hormone (PTH) have led many investigators to conclude that levels of 25-OHD greater than 32 ng/mL (80 nmol/L) are necessary to prevent a rise in PTH (and bone loss, by inference). It has been estimated that a vitamin D intake as high as 100 µg/d would be needed to attain these levels in light-skinned people residing in northern latitudes.

Many studies supporting vitamin D supplementation have been performed in elderly patients who require greater quantities of vitamin D to prevent secondary hyperparathyroidism. Clinical trials evaluating the effect of vitamin D supplementation on loss of bone density in midlife have produced conflicting results. Some of these trials have combined calcium with vitamin D supplements, so that it is unclear which nutrient is responsible for the observed benefit. Another confounding factor in interpreting previous trials is that reducing bone resorption may result in a temporary alteration in the remodeling space with an increase in bone density that is limited to the length of the remodeling cycle.

As a result of reduced dermal synthesis of vitamin D, black women have lower serum levels of 25-OHD than white women. In a preliminary short-term study, we observed a reduction in bone turnover markers with supplementation of 20 µg/d. We hypothesized that...
vitamin D supplementation would decrease postmenopausal bone loss in African American women. To test our hypothesis, we performed a randomized, double-blind, 3-year trial comparing bone loss with vitamin D₃ supplementation vs bone loss with placebo. Both groups received calcium supplements to ensure dietary calcium sufficiency. To our knowledge, this study is the first clinical trial examining the effect of vitamin D on bone loss in African American women.

**METHODS**

**PARTICIPANTS**

Ambulatory postmenopausal African American women not receiving hormone therapy were recruited from the Long Island community (Figure 1). All participants provided written informed consent, and the trial was approved by the institutional review board of Winthrop University Hospital, Mineola, NY. African American ancestry of the participants was assessed by self-declaration that both parents and at least 3 of 4 grandparents were African American. Exclusion criteria included previous treatment with bone active agents and any medication or illness that affects skeletal metabolism.

**STUDY DESIGN**

The participants were randomly assigned using a computer-generated sequence to receive either 20 µg/d of oral vitamin D₃ or a matched placebo. After 24 months, the dose of vitamin D₃ was raised to 50 µg/d in the calcium plus vitamin D (Ca + D) group. The dose was revised at the suggestion of the Data Safety Monitoring Board because of a growing consensus in the literature that 20 µg of vitamin D₃ might not produce optimal serum levels of 25-OHD. The upper limit of vitamin D intake recommended by the Food and Nutrition Board is 50 µg/d. Calcium intake was assessed by food frequency at each visit, and supplements were given to both groups to ensure a total daily calcium intake of 1200 to 1500 mg. Vitamin D₃ (20 µg and 50 µg capsules) and matched placebo capsules were custom manufactured for the study (Tishcon Corp, Westbury, NY). Vitamin D₃ content was also analyzed in an independent laboratory (Vitamin D, Skin, and Bone Research Laboratory, Department of Medicine, Boston University School of Medicine, Boston, Mass). The calcium supplements were provided as calcium carbonate.

**OUTCOME VARIABLES**

Bone mineral density was measured at 6-month intervals at the total hip, nondominant midradius, whole body, and spine (anteroposterior) with a dual-energy x-ray absorptiometer (model QDR 4500, version 9.80D; Hologic Inc, Waltham, Mass). The coefficient of variation at our center for lumbar spine (L1-L4) is 0.81%; total hip, 0.62%; total body, 0.49%; and midradius, 0.78%.

**LABORATORY TESTS**

A fasting blood sample was collected for serum chemical analysis, calcium, PTH, 25-OHD, 1,25 dihydroxyvitamin D [1,25 (OH)₂D₃], osteocalcin, and CrossLaps (C-terminal telopeptide of type I collagen; Nordic Bioscience Diagnostics, Herlev, Denmark) at baseline and at 3, 6, 12, 18, 24, 27, 30, and 36 months as was a 24-hour urine sample for calcium. Serum PTH was measured by the Allegro intact-PTH immunoassay purchased from Nichols Institute Diagnostics (San Juan Capistrano, Calif). Serum 25-OHD was measured by radioimmunoassay using a kit manufactured by DiaSorin Inc (Stillwater, Minn). Serum 1,25(OH)₂D₃ was measured using commercial kits also manufactured by DiaSorin Inc. The assay involves a preliminary extraction and subsequent purification using C₁₈ OH cartridges. Following extraction, the treated sample was then assayed using a competitive radioimmunoassay procedure based on a polyclonal antibody that is specific for both 1,25(OH)₂D₃ and 1,25(OH)₂D₄. Serum osteocalcin and serum CrossLaps were measured by a 1-step enzyme-linked immunoabsorbent assay (Nordic Bioscience Diagnostics).

**STATISTICAL ANALYSIS**

The primary end point for this study was the BMD of the total hip. An intention-to-treat approach that included all data was followed in all primary analyses. We analyzed longitudinal outcome variables with repeated measures regression models, using the PROC MIXED software (SAS, version 8.2; SAS Inc, Cary, NC). The significance of different BMD slopes between treatment groups was tested by examining the interaction of group
and time. The study was designed for an active placebo differential BMD percent change per year of 0.36 with a power of 0.80. The slope over 3 years was divided by baseline to derive an annualized percent change from baseline per year. Comparisons of weighted mean slopes between groups was performed by independent t tests, the weight being the inverse of the variance of each estimated slope. No interim analyses were performed. Post hoc analyses included the linear correlation of each individual’s rate of BMD change over time with the mean serum 25-OHD level in the course of study. In addition, analysis of the linear correlation of each individual’s rate of BMD change over time with their variance of each estimated slope. No interim analyses were performed. Post hoc analyses included the linear correlation of each individual’s rate of BMD change over time with their variance of each estimated slope.

RESULTS

BASELINE CHARACTERISTICS

The baseline demographic profile and laboratory values of the study population are summarized in Table 1. There were no significant differences between the 2 groups. A majority of the participants had some college experience. The women had moderately active lifestyles. Approximately 47% were taking supplemental calcium and/or vitamins at baseline. Seven percent of the women smoked. The initial BMD at the total hip for the whole cohort ranged from normal (65.0%) to osteopenic (33.6%) to osteoporotic (1.4%) with a mean T-score of −0.59±0.84 (range, −2.9 to 1.7) using black women from the third

### Table 1. Baseline Values for Demographics, Bone Mineral Density, and Laboratory Values

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Ca Group (n = 104)</th>
<th>Ca-D Group (n = 104)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>61.2 ± 6.3</td>
<td>59.9 ± 6.2</td>
</tr>
<tr>
<td>Height, cm</td>
<td>161.4 ± 6.1</td>
<td>162.7 ± 6.6</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>79.2 ± 12.6</td>
<td>78.0 ± 13.6</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>30 ± 4</td>
<td>29 ± 4</td>
</tr>
<tr>
<td>Smoking, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current user</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Former user</td>
<td>40</td>
<td>35</td>
</tr>
<tr>
<td>Dietary vitamin D intake, µg/d</td>
<td>4.6 ± 4.2</td>
<td>4.6 ± 4.8</td>
</tr>
<tr>
<td>Calcium intake, mg/d</td>
<td>756 ± 541</td>
<td>762 ± 623</td>
</tr>
<tr>
<td>BMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total hip, g/cm²</td>
<td>0.946 ± 0.116</td>
<td>0.932 ± 0.146</td>
</tr>
<tr>
<td>Radius, g/cm²</td>
<td>0.614 ± 0.061</td>
<td>0.619 ± 0.067</td>
</tr>
<tr>
<td>Total body, g/cm²</td>
<td>0.940 ± 0.074</td>
<td>0.934 ± 0.095</td>
</tr>
<tr>
<td>Spine, g/cm²</td>
<td>1.005 ± 0.142</td>
<td>0.984 ± 0.155</td>
</tr>
<tr>
<td>25-OHD, ng/mL</td>
<td>17.2 ± 6.64</td>
<td>19.3 ± 8.36</td>
</tr>
<tr>
<td>1,25(OH)2D, pg/mL</td>
<td>45.7 ± 15.10</td>
<td>46.5 ± 15.2</td>
</tr>
<tr>
<td>PTH, pg/mL</td>
<td>42.4 ± 18.4</td>
<td>44.2 ± 19.3</td>
</tr>
<tr>
<td>Osteocalcin, ng/mL</td>
<td>14.5 ± 7.4</td>
<td>16.3 ± 8.2</td>
</tr>
<tr>
<td>Serum CrossLaps, ng/mL</td>
<td>0.318 ± 0.140</td>
<td>0.345 ± 0.149</td>
</tr>
</tbody>
</table>

Abbreviations: BMD, bone mineral density; BMI, body mass index; Ca, calcium; D, vitamin D; PTH, parathyroid hormone.

SI conversion factors: To convert 25-hydroxyvitamin D (25-OHD) to nanomoles per liter, multiply by 0.106; parathyroid hormone to nanomoles per liter, multiply by 0.172; serum CrossLaps to picomoles per liter, multiply by 7750.

National Health and Nutrition Examination Survey20 as the reference. The baseline 25-OHD levels ranged from 5 to 40 ng/mL (12.5 nmol/L to 99.7 nmol/L) with a mean level of 18.8 ng/mL (47 nmol/L) in the study population (Table 1, Figure 2).

ADHERENCE

Mean pill count compliance was 87%±8% of vitamin D pills consumed after the randomization visit. Approximately 96%±7% of the subsequent visits were kept by our patients. Mean daily calcium intake including supplements was 1312±153 mg/d in the calcium-alone (Ca) group and 1349±204 mg/d in the Ca+D group.

BONE DENSITY CHANGES

There was no difference in the rate of bone loss between the Ca+D group compared with the Ca group at any time during the 3 years of study duration (Figure 3). Correlation analysis also failed to show any relationship between serum 25-OHD levels and bone density change in either group alone or in the combined groups. There were statistically significant declines in BMD per year at each measurement site, except for the lumbar spine, over the 3-year study period in both groups. The overall change in BMD at the total hip among the participants was −0.40%±1.8% (95% CI, −0.6% to −0.0%) and 0.25% (95% CI, −0.03% to 0.68%) in the Ca group compared with the Ca+D group. The nonsignificant increase in BMD of the lumbar spine was +0.3% in the Ca group (95% CI, −0.1% to +0.6%) and 0.25% (95% CI, −0.1% to +0.6%) in the Ca+D group.

An analysis of the linear correlation of each individual’s rate of BMD change over time with the mean serum 25-OHD level attained in the course of the study revealed no association. Other analyses examining those with low baseline 25-OHD or high PTH also showed no influence of 25-OHD on BMD changes.
Although the overall trend was loss in BMD over 3 years, over the first year there was a statistically significant and substantial increase in BMD at all sites (except the lumbar spine) in both study groups (Figure 3), generally at a magnitude of between 1.1% and 1.3% (\(P < .001\)). The lumbar spine increased by only half that amount (0.6% over the first year). Changes over the second and third years revealed a significant change in BMD of the total body, hip, and radius from −1.0% to −1.6% per year (\(P < .001\)), whereas there was virtually no change in the lumbar spine during that period.

LABORATORY VALUES

Mean serum 25-OHD levels increased in the Ca + D from a baseline of 18.8 ng/mL (46.9 nmol/L) (95% CI, 17.6-20.4 ng/mL [43.9-50.9 nmol/L] to 28.4 ng/mL (70.8 nmol/L) (95% CI, 26.6-30.5 ng/mL) [66.4-76.1 nmol/L]) (\(P < .001\)) with 3 months of 20 µg/d vitamin D\(_3\) supplementation and to 34.8 ng/mL (86.9 nmol/L) (95% CI, 32.1-37.7 ng/mL [80.1-94.1 nmol/L]) (\(P < .001\)) 3 months following the increase in dose to 50 µg/d. The serum 25-OHD levels in the Ca group did not change significantly throughout the study. The final distribution of 25-OHD levels in the active group revealed that about 40% of postmenopausal women still had serum 25-OHD levels of less than 32 ng/mL (8.0 nmol/L) despite 50 µg/d of vitamin D\(_3\) supplementation. A decline in PTH levels at 3 months in both groups was not sustained. Serum 1,25(OH)\(_2\)D levels also declined at 3 months in the Ca group but not in the Ca + D group. The bone markers, serum osteocalcin, and CrossLaps did not reveal any significant differences between the 2 groups.

ADVERSE EVENTS

A total of 222 adverse events were reported in the study over 3 years. There were 15 serious adverse events, 8 in the Ca + D group and 7 in the Ca group. None of these adverse events were considered to be related to the study. There were 9 isolated incidences of mild hypercalcemia (6 in the Ca + D group and 3 in the Ca group), which were in the reference range on repeated sampling. Similarly, isolated episodes of elevated 24-hour urinary calcium excretion (>5 mg/kg per day) were observed among 4 participants (3 in the Ca + D group, 1 in the Ca group). Calcium supplements were discontinued in 1 participant. There was a slight increase in serum calcium and urinary calcium excretion over 3 years in both the Ca + D and the Ca groups, but these levels remained within the reference range for healthy adults in all participants (Table 2). There were no episodes of nephrolithiasis.
We found no benefit of vitamin D₃ supplementation over calcium supplementation alone in preventing bone loss in postmenopausal African American women. Moreover, we found no evidence for a relationship between serum 25-OHD levels and rates of bone loss. Although there have been several trials including white women with serum 25-OHD levels and rates of bone loss, we found no evidence for a relationship between 25-OHD levels greater than 20 ng/mL (50 nmol/L) at baseline and the greater decline in PTH levels, those with 25-OHD levels less than 20 ng/mL (50 nmol/L) might benefit from vitamin D supplementation. Furthermore, in some studies that concluded that vitamin D prevents fractures, calcium supplements were included in the vitamin D group but not the placebo group. Because a number of trials have suggested anti-fracture efficacy of calcium alone, it is unknown if the vitamin D or the calcium provided the benefit.34-36

Consideration in interpreting bone loss rates should also be given to the remodeling transient, a temporary alteration in the balance between bone formation and bone resorption brought about by any factor that reduces bone resorption. Clinical trials using BMD as an end point usually employ linear regression analyses to calculate rates of loss. As a result, a 2- to 3-year study may show a positive response to an antiresorptive agent even if the increase occurred only in the first year as a result of the remodeling transient. We detected a remodeling transient effect in our study that we believe was due to calcium supplementation. Examination of previous trials suggest that the observed benefit from vitamin D supplements may have reflected the remodeling transient and would not necessarily be sustained.17

Vitamin D supplementation was not associated with any significant adverse effects. This confirms the demonstration by others that even higher quantities of vitamin D supplements are safe.37 Importantly, in our study the safety of vitamin D supplements was evaluated in a state of calcium sufficiency. Our study demonstrated a lack of benefit of vitamin D supplementation on loss of skeletal mass in calcium-sufficient African American women in midlife. Although this may not be extrapolated to women of other ethnic groups, to elderly women, or to greater degrees of vitamin D insufficiency, it lends support to reexamination of optimal vitamin D nutrition for skeletal health in postmenopausal women of other ethnic groups.

Accepted for Publication: March 14, 2005.
Correspondence: John F. Aloia, MD, Winthrop University Hospital, 222 Station Plaza North, Suite 510, Mineola, NY 11501 (jaloha@winthrop.org).
Funding/Support: This research was funded by the National Institute of Aging (RO1 AG15325), National Institutes of Health, Bethesda, Md.

Acknowledgment: We thank members of the Data Safety and Monitoring Board: Robert Recker, MD, Marjorie Luckey, MD, Michael Borenstein, PhD, Charles Hollingsworth, MD, PhD, Sherry Sherman, PhD, and Joanna Badanelli, MD. We thank Michael Holick, MD, PhD, and Tai Chen, PhD, for an independent assessment of vitamin D content of our study medication. We also thank Sharon Sprinz, RT, Jane Moore, RN, and Martin Feuerman, MS, for their expertise and Audrey Gallo-Neglia for preparation of the manuscript.

REFERENCES


